

March 3-5, 2026 | Boston, MA
www.as-immunetolerance.com

Register & Pay By
Monday, March 2 &
Save up to \$200



9th Annual

Antigen-Specific Immune Tolerance Summit

Pioneering Precision Immunology to Transform Autoimmune & Allergic Disease Treatment

Driving Clinical Success in Autoimmune & Allergic Disease Treatment via Mechanistic Insights, Biomarker Validation, Antigen Delivery & Clinical Trial Design

Expert Speakers Include:



Aaron Winkler
Senior Scientific
Director, Immune
Tolerance Lead
& Inflammation,
Immunology
Pfizer



Jason Noon
Associate Director,
Head, Research
& Immune Cell
Depletion Group
AbbVie



Peter Strumph
Chief Executive
Officer
Parvus Therapeutics



**Agnete Brunsvik
Fredriksen**
Chief Scientific
Officer & Business
Development
**Nykode
Therapeutics**



Anton Lindqvist
Chief Scientific
Officer
Diamyd



Cristina de Min
Chief Medical Officer
Topas Therapeutics

Proud to Partner With:

Aravax

COUR



Immunotolerx



Novoviah
Ultra-sensitive T cell testing in patients



GENEDIT
GENE THERAPY DELIVERED

+1 617 455 4188 @ info@hansonwade.com

www.as-immunetolerance.com Antigen-Specific Immune Tolerance



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Uniting Pharma & Biotech Leaders Progressing ASIT Targeted Therapeutics

9th Annual
Antigen-Specific
Immune Tolerance Summit
March 3-5, 2026 | Boston, MA

Antigen-specific immune tolerance therapies are rapidly advancing towards the clinic, with novel modalities including CAR-T and mRNA, first-in-human trials, and landmark readouts shaping the field. The **9th Antigen-Specific Immune Tolerance Summit** is the only meeting dedicated exclusively to progressing ASIT targeted therapeutics from target discovery through to durable efficacy in the clinic across autoimmune and allergic diseases.

Bringing together **60+ experts** across autoimmune and allergic disease research and therapeutic development, this meeting dives into the key scientific, translational, and clinical hurdles to unlock the game-changing potential of curative therapies that go beyond immunosuppression.

From dissecting antigen selection in complex diseases, to defining biomarkers of tolerance, optimizing antigen delivery platforms, uncovering emerging insights into B-cell biology, depletion, and cellular tolerance, and navigating clinical trial design, the ASIT summit provides the full scope of content and connections essential to driving innovation.

This is the must-attend industry forum for those seeking to accelerate the next generation of antigen-specific immune tolerance therapies to patients with type 1 diabetes, multiple sclerosis, rheumatoid arthritis and beyond. Join your colleagues from discovery through to clinical development from leading companies including **AbbVie**, **COUR**, **Diamyd**, **Topas**, **Pfizer**, **Parvus**, and more to make last connections and extract key strategies to propel your pipeline forward.

What Our Speakers have to Say

“Really great meeting! All the talks were high quality and sufficiently diverse to cover a lot of different angles. Everything ran smoothly and was effective for our team both to learn from others and also promote our own work”

Geoffrey Lynn, Chief Scientific Officer,
Barinthus bio

“The friendliness and collaborative nature, and the focus on the pressing questions related to all companies”

Dan Ferullo, Director,
Therapeutic Platform,
Zag Bio

Key Benefits of Attending

COUR
DIAMYD
MEDICAL

Preview fresh clinical readouts from pioneering ASIT leaders, including **COUR** and **Diamyd**, and understand their challenges and priorities for the next 12 months

TSCAN
THERAPEUTICS

Discover how **TScan Therapeutics** is bridging antigen discovery to precision therapeutic design for ASIT, from their learnings in oncology, to bridge the translational gap that persists in autoimmune disease

Aravax

Gain cross-functional insights from late stage peanut allergy trials and proof-of-concept studies with **Aravax** which has led to late phase II clinical trials

Integrated
nanotherapeutics
moderna

Discover cutting-edge mRNA approaches to ASIT from **Integrated Nanotherapeutics** and **Moderna**, and their strategies going forward into their first in-human trials

abbvie
RheumaGen

Go beyond traditional ASIT-exploring gene therapy advances in rheumatoid arthritis, and precision targeting of T- and myeloid-cell subsets to improve durability and tolerability with **AbbVie** and **RheumaGen**

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Expert Speakers

5th Annual
**Antigen-Specific
Immune Tolerance Summit**
March 3-5, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Pharma Experts



Jason Noon
Associate Director, Head,
Research & Immune Cell
Depletion Group
AbbVie



David Easterhoff
Director, Autoimmunity
Moderna



Aaron Winkler
Senior Scientific Director,
Immune Tolerance Lead &
Inflammation, Immunology
Pfizer

Biotech Masters



Bruna Barneda
Chief Operating Officer
Ahead Therapeutics



Sara Prickett
Chief Scientific Officer
Aravax



Geoffrey Lynn
Advisor & ASIT Program
Scientific Lead
**Barinthus
Biotherapeutics**



Charlotte Fribert
Chief Executive Officer
Bonsai Biotherapeutics



Adam Elhofy
Vice President & Research
& Collaborations
COUR Pharma



Anton Lindqvist
Chief Scientific Officer
Diamyd Medical



To Be Announced
GenEdit



Ernest Smith
Chief Executive Officer
Immunotolerx Inc



Heather Denroche
Director, Preclinical
Development
**Integrated
Nanotherapeutics**



**Agnete Brunsvik
Fredriksen**
Chief Scientific Officer &
Business Development
Nykode Therapeutics



Michael Engsig
Chief Executive Officer
Nykode Therapeutics



Peter Strumph
Chief Executive Officer
Parvus Therapeutics



Brian Freed
Chief Scientific Officer
RheumaGen



Poh Yeh-Chuin
Vice President & Head,
Technical Operations
Tolerance Bio



Cristina de Min
Chief Medical Officer
Topas Therapeutics



Andrew Ferretti
Director, Technology &
Platform Discovery
Tscan Therapeutics



John Kulman
Chief Scientific Officer
Zag Bio

Academic Specialists



José Carballido
University Lecturer
University of Basel

Pre-Conference | Workshop Day

Tuesday, March 3, 2026

Antigen-Specific Immune Tolerance Summit
March 3-5, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Check-In

8.30

Workshop A

9.00

Detecting, Quantifying & Interpreting Antigen-Specific Biomarker Activity as Programs Move from Preclinical to Clinical Stages

The discussion will focus on what has and hasn't worked, why translation gaps persist for ASIT trials in T1D, MS, rheumatoid arthritis, celiac disease and other autoimmune diseases. Covering robust biomarker strategies for patient stratification, mechanistic endpoints, and proof-of-mechanism studies. Topics include measuring rare antigen-specific cells, emerging technologies, non-invasive monitoring - from immune phenotyping to leveraging preclinical models to de-risk studies.

Perfect to bring your team to provide a shared framework to understand the success and failures in ASIT programs. Join this workshop to:

- Understand the limitations of current antigen-specific biomarkers (e.g., tetramers, AIM assays) and how new technologies are addressing sensitivity and reproducibility issues
- Learn how leading labs are using biomarkers to stratify patients and define mechanistic endpoints in ongoing T1D and MS trials
- Identify strategies to bridge preclinical and clinical biomarker data, improving the predictivity of immune tolerance therapies

Workshop Leaders



José Carballido
University Lecturer
University of Basel

Lunch

12.00

Workshop B

1.00

Proof in the Patients: Strategic Approaches to Advancing Tolerizing Therapies into Successful Clinical Trials

This workshop will focus on clinical strategy for ASIT from concept to clinical proof. It will explore how companies are generating proof of mechanism and proof of concept data, selecting the right patient populations, and designing trials that can show durable clinical benefit. Drawing on experiences from successful mechanistic readouts using biomarker-driven approaches to lessons from less successful trials to explore what has and hasn't translated effectively into clinical benefit. Participants will debate what level of efficacy, durability, and regulatory evidence is needed for clinical and commercial success.

Key questions to be answered:

- How can early-phase trials best demonstrate proof of mechanism and proof of concept in tolerizing therapies?
- What are the priority considerations moving from healthy-volunteer studies to patient-based proof-of-mechanism designs?
- What lessons from past antigen-specific programs can improve antigen selection, delivery, and trial design?
- What trial strategies have best translated mechanistic signals into durable, clinically meaningful outcomes?
- What level of durability, dosing practicality, and clinical benefit will regulators and clinicians expect for tolerizing therapies to gain acceptance?

Workshop Leaders



Charlotte Fribert
Chief Executive Officer
Bonsai Biotherapeutics



George Smith
Co-Founder & Chief Executive Officer
Desna Therapeutics

End of Pre-Conference Workshop Day

4.00

Conference Day One

Wednesday, March 4, 2026

Antigen-Specific Immune Tolerance Summit
March 3-5, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



7.30 Check In, Coffee & Light Breakfast



José Carballido
University Lecturer
University of Basel

8.25 Chair's Opening Remarks

Clinical Trial Readouts in Precision Immunotherapy: Biomarker-Driven Insights, Adaptive Dosing & Translational Advances Across Autoimmune Programs



Anton Lindqvist
Chief Scientific Officer
Diamyd Medical

8.30 Approaching Proof of Concept for Antigen-Specific Immunotherapy in Type 1 Diabetes - Precision Therapy in HLA DR3-DQ2 Patients

- Updates from the ongoing DIAGNODE-3 Phase 3 trial (interim readout expected March, 2026)
- Review of pharmacodynamic effects of rhGAD65 treatment
- Evidence of disease-modifying benefit in Stage 3 Type 1 diabetes and strategy to guide next-phase development and future precision-medicine strategies



Adam Elhofy
Vice President,
Research
COUR Pharma

9.00 Clinical Signatures of Tolerance: PBC Prognostic Scores, Responder Dynamics & MG Applications

- Explore in-depth clinical analyses of PBC including UK-PBC scoring, ALBI/GLOBE metrics, and emerging biomarkers to understand how tolerance influences disease prognosis
- Highlight responder outcomes, including responder-rate evaluation and responder-curve profiling following tolerance induction
- Delve into how these findings support translation into myasthenia gravis (MG), outlining clinical implications and future development strategy



Cristina de Min
Chief Medical Officer
Topas Therapeutics

9.30 Topas: Overcoming Tetramer-Based Detection Challenges Integrating Trial Design, Endpoint Selection & Analytical Methods to Evaluate Antigen-Specific Tolerance Induction

- Integration of biology with clinical trial design to evaluate antigen-specific tolerance induction, drawing on Phase I and II experience across celiac disease
- Endpoint selection guided by both mechanistic and clinical relevance, including strategies for incorporating non-invasive biomarkers and disease-appropriate readouts
- Analytical methods used to assess antigen-specific responses and evolving approaches to improve sensitivity and reliability



Sara Prickett
Chief Scientific Officer
Aravax
NEW DATA

10.00 Rationally Designed Peptide Immunotherapy for Peanut Allergy: Bringing Antigen-Specific Immune Tolerance into Late-Stage Clinical Reality

- Exploring Aravax's peptide-based immunotherapy that is designed to induce antigen-specific immune tolerance by precisely targeting T-cells
- Delving into the translational strategy that has led to late Phase II clinical trials



10.30 Speed Networking

This informal session provides the perfect opportunity to connect with industry pioneers and key opinion leaders. Establish meaningful connections to build upon at the rest of the conference and gain exclusive first-hand insights into the latest research and developments driving progress in the space.



11.00 Morning Break & Refreshments

Conference Day One

Wednesday, March 4, 2026

Antigen-Specific
Immune Tolerance Summit
March 3-5, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Defining & Aligning Success in Antigen-Specific Immune Tolerance: Clinical, Strategic & Investment Perspectives



Aaron Winkler
Senior Scientific
Director
Pfizer



Michael Engsig
Chief Executive Officer
Nykode Therapeutic

11.30 Panel Discussion: Defining Success in Antigen-Specific Immune Tolerance

- What does true success look like in ASIT - single-dose cures, durable remission, or reduced treatment burden?
- How can the field align on shared clinical benchmarks as we move from preclinical to human data?
- What lessons can be drawn from broader immunology approaches, such as B-cell depletion, allergy learnings and tolerance induction?
- How do current clinical outcomes compare between targeted tolerance and broader immunoregulatory mechanisms?



To Be Announced
GenEdit

12.00 Session Details to be Announced



12.30 Lunch

Mechanistic Insights Across Immune Tolerance: Leveraging Antigen-Specific & Cross-Disease Learnings to Guide Therapy Development



Heather Denroche
Director, Preclinical
Development
**Integrated
Nanotherapeutics**
NEW DATA

1.30 Advancing mRNA-LNP Autoantigen Therapies: Engineering Peripheral Tolerance & Driving Toward First-in-Human Studies

- Explore how mRNA-LNPs can be engineered to drive peripheral tolerance
- Delve into preclinical data in type 1 diabetes and additional pipelines
- Discuss the translational trajectory toward first-in-human studies



David Easterhoff
Director, Autoimmunity
Moderna
NEW DATA

2.00 Mechanistic Insight to Leverage mRNA LNPs For ASIT in Autoimmune Disease

2.30 A Phosphatidylserine-Inspired Lipid Nanoparticle (LNP) Platform for Antigen-Specific Immune Tolerance



Ernest Smith
Chief Executive Officer
Immunotolerx Inc.

- The Immunotolerx platform employs phosphatidylserine (PS)-containing lipid nanoparticles to re-educate the immune system and induce antigen-specific immune tolerance
- This approach harnesses the endogenous apoptotic cell clearance mechanism, in which PS-bearing nanoparticles engage PS receptors on macrophages and dendritic cells, biasing antigen presentation toward regulatory T-cell induction and suppression of pathogenic immune responses
- The platform has been validated across multiple in vitro and in vivo studies and is supported by more than 25 peer-reviewed publications

Conference Day One

Wednesday, March 4, 2026

Antigen-Specific Immune Tolerance Summit
March 3-5, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



2.40 Afternoon Break & Scientific Poster Session

Want to share your work but not ready for the big stage just yet? The Scientific Poster Session is your prime time to share your work with peers from various backgrounds, all focused on ASIT therapeutics. Gain feedback on how you can accelerate the progression of your drug pipelines and build connections for potential collaborations to take your therapeutic from discovery to market.



Peter Strumph
Chief Executive Officer
Parvus Therapeutics

3.10 Driving Proof-of-Mechanism & Scalable Treg Therapy Development

- Translating discovery into the clinic by driving research from early discovery through preclinical validation, ensuring robust study design, regulatory alignment, and effective transition of lab findings into first-in-human studies
- Leveraging a tetramer-based assay to directly measure antigen-specific Treg populations, enabling precise proof-of-mechanism validation
- Establishing scalable GMP manufacturing processes that bridge scientific innovation and clinical application, ensuring efficient development of patient-ready therapeutics

Advancing the Future of ASIT: Streamlining Manufacturing & Regulatory Pathways to Deliver Safe, Scalable & Impactful Therapies



Peter Strumph
Chief Executive Officer
Parvus Therapeutics

3.40 Roundtable Discussion: Industrializing ASIT: Solving Manufacturing Challenges While Building Regulatory & Commercial Readiness

- Role of cell therapy in autoimmune disease, significance and cost effectiveness
- Examining both ex vivo and in vivo approaches, highlighting the trade-offs between customized manufacturing and off-the-shelf therapies
- Evaluating current GMP-level processes which remain largely manual, creating bottlenecks in speed, cost, and reproducibility
- Discussing automated technologies, such as advanced cell sorters and bioreactors, that could streamline manufacturing



José Carballido
University Lecturer
University of Basel

4.10 Chairs Closing Remarks

“The interaction sessions with experts from different fields were impressive and enjoyable”

Paul Chen, Principal, Scientist, AbbVie

Conference Day Two

Thursday, March 5, 2026

Antigen-Specific
Immune Tolerance Summit
March 3-5, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Check In, Coffee & Light Breakfast



José Carballido
University Lecturer
University of Basel

8.55 Chair's Opening Remarks

Targeted Antigen Presentation & Human-Centred Biomarker Models Driving Safer & Durable Immune Tolerance



Geoffrey Lynn
Advisor & ASIT
Program Scientific
Lead
Barinthus
Biotherapeutics
NEW DATA

9.00 Interim Clinical Results for VTP-1000, an IM-Administered ASIT Therapy for Celiac Disease

- SNAP-TI is an ASIT platform that enables co-delivery of multiple unique peptide antigens and rapamycin in nanoparticles of precise size and composition for local (IM or SC) administration
- VTP-1000 is a candidate for celiac disease based on SNAP-TI
- Updates on the VTP-1000 clinical program including safety and immunology parameters will be presented



Agnete Brunsvik Fredriksen
Chief Scientific
Officer & Business
Development
Nykode Therapeutics
NEW DATA

9.30 Precision Therapy: Achieving Precisely Controlled & Safer Immune Tolerance Through Antigen-Presenting Cell-Subtype-Specific Delivery

- Engineered vaccine variants that target antigens to defined immune cell subsets, triggering the immune system in distinct directions depending on which APC that receive the antigen
- Fine-tune immune outcomes to drive preferential effects on autoantibodies, regulatory T cells, and effector cells achieving a level of control unmatched in the field
- Compare versions across sophisticated transgenic models to precisely measure cytokine responses in low-frequency cell populations and define disease-specific immune modulation



10.00 Roundtable Discussion: Utilising Human-Centred Models with Applicable Biomarker-Drive Mechanism-Based Insights & Durable Immune Tolerance

- Develop models to mirror human disease biology to create predictive mechanically relevant models for autoimmune conditions
- Explore the growing interest in in vitro and biomarker-based models that could complement or replace animal studies
- Discuss the significance of immune phenotypes in mice or other animals, their relevance to human biology, and whether these changes can drive long-lasting immune tolerance



10.30 Morning Break & Networking

Targeting Immune Cell Pathways to Drive Durable Tolerance: Integrating T & B Cell Modulation for Next-Generation ASIT



Jason Noon
Director, Immunology
Discovery
AbbVie

11.00 Beyond B-Cell Depletion: Targeting Pathogenic T-& Myeloid-Cell Subsets to Achieve Durable Autoimmune Remission

- Explore T-cell subsets beyond B-cell depletion—particularly tissue-resident memory, follicular helper, and peripheral helper T cells—as key drivers of autoimmune persistence and B-cell activation
- Examine evidence that selective depletion or modulation of these T-cell and myeloid populations may deliver deep, durable disease control comparable to B-cell-targeted approaches
- Address translational challenges including efficient tissue-level depletion, optimizing delivery and biodistribution of therapeutic modalities, and defining biomarkers that capture local immune modulation

Conference Day Two

Thursday, March 5, 2026

Antigen-Specific
Immune Tolerance Summit
March 3-5, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Bruna Barneda
Chief Operating Officer
Ahead Therapeutics
NEW DATA

11.30 Modulating T-& B-Cell Interactions to Achieve Durable Immune Tolerance in ASIT

- Ahead MiMiTOPs display a broad, cross-disease mechanism of action
- Antigen-presenting cells from patients with T1D, RA, MG, MS-and iTTP acquire a tolerogenic phenotype following interaction with MiMiTOPs. Dendritic cells and macrophages become tolerogenic, reducing their ability to drive autoreactive T-cell proliferation, while B lymphocytes directly internalize MiMiTOPs and secrete TGF- β and IL-10, adopting an immunoregulatory phenotype
- Through coordinated effects on innate and adaptive immunity, MiMiTOPs provide an antigen-specific strategy to support long-term immune tolerance



12.00 Lunch & Networking Break

Next-Generation Autoimmune Cell Therapies Through T-Cell Target Discovery & Streamlined Gene-Edited Development



Andrew Ferretti
Director, Technology &
Platform Discovery
TScan Therapeutics

1.00 TScan's Antigen Discovery Platform Enables Tolerizing Therapies Through Identification of CD8⁺ and CD4⁺ T-Cell Targets

- Introduction to TargetScan, a cell-based, unbiased platform that pairs naturally presented antigens with their cognate TCRs
- Demonstration of TargetScan's ability to identify both CD8⁺ and CD4⁺ T-cell targets in example indications such as ankylosing spondylitis, birdshot uveitis, scleroderma, and ulcerative colitis
- Exploration of novel biologically validated targets that enable antigen-specific tolerizing therapies in indications such as ankylosing spondylitis



Brian Freed
Chief Scientific Officer
RheumaGen
NEW DATA

1.30 Advancing Gene-Edited Cell Therapies in Rheumatoid Arthritis: Streamlined Clinical Development for Multi-Indication Translation

- Highlighting a platform-centric gene-editing strategy that harmonizes clinical protocols and manufacturing processes, enabling a single target modification to be applied across multiple autoimmune indications
- Showcasing a multi-indication clinical development pathway that leverages Phase I safety and mechanistic insights to accelerate Phase II expansion, streamlining translation across diverse disease contexts



2.00 Afternoon Break

Re-Engineering Central Immune Tolerance Through Thymic Biology & Regenerative Cell Therapy



John Kulman
Chief Scientific Officer
Zag Bio

2.30 Targeting the Thymus to Transform Outcomes in Autoimmune Disease

- Comparison of regulatory T cells, peripheral regulatory T cells, and alternative immune-tolerance mechanisms, highlighting their distinct biology and therapeutic relevance
- Reviewing current preclinical and emerging clinical evidence, outlining how each approach contributes to immune modulation
- Insights into key challenges, translational hurdles, and notable successes that are shaping the future development of targeted immunotherapies

Conference Day Two

Thursday, March 5, 2026

Antigen-Specific
Immune Tolerance Summit
March 3-5, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Poh Yeh-Chuin
Vice President & Head,
Technical Operations
Tolerance Bio

3.00 Rebuilding Central Tolerance: Translating iPSC-Derived Thymic Cell Therapies Into the Clinic

- Exploring the thymus - the central organ responsible for establishing and maintaining immune tolerance
- Development of iPSC - derived thymic cells that demonstrate in vivo T-cell education to re-establish central tolerance in immune-related diseases
- Unlocking the potential of thymus - based regenerative medicine to restore immune balance



José Carballido
University Lecturer
University of Basel

3.30 Chair Closing Remarks

■ ■ Small meeting, relevant focus, mainly industry, easy opportunity to network/interact and ask questions, hearing relevant presentations from industry presenterse ■ ■

Sara Prickett, Chief Scientific Officer, Aravax



Expertise Partner

www.genedit.com

Aravax

Industry Partner

Our next-generation immunotherapies use proprietary engineered peptides designed to precisely retrain the immune system to tolerate specific foods whilst avoiding treatment-induced acute allergic reactions, to produce safe and convenient treatments for food allergies.

Aravax's lead product for peanut allergy (PVX108) is currently being tested in Phase 2 trials in adolescents and children at clinics in Australia and the United States.

Aravax was founded in May 2015 from intellectual property developed by Alfred Health and Monash University, and investment from the Medical Research Commercialisation Fund (MCRF), managed by Brandon Capital Partners.

As part of closing a Series B funding round in January 2024, Aravax welcomed new investors Novartis Venture Fund, Tenmile, Breakthrough Victoria, Uniseed, and UniSuper to support the Phase 2 development of PVX108 and expand the product pipeline.

www.aravax.com.au

COUR

Industry Partner

Our first-in-class, disease-modifying, targeted therapies are designed to safely regulate and attenuate the immune system. Backed by compelling preclinical and clinical data, our groundbreaking treatments have demonstrated the potential to induce targeted immune tolerance where the body is no longer targeting itself, offering new hope for patients with a range of autoimmune diseases.

Our versatile platform technology uses an antigen-specific approach to precisely treat the underlying autoimmune disease to stop inflammatory destruction while preserving the normal immune function.

By leveraging the body's constant endogenous pathway for reinforcing self-tolerance, our technology can be leveraged to target a wide range of immune-mediated diseases

www.courpharma.com

Get Involved



Malik Mellal
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com



Innovation Partner

Immunotolerx Inc. is advancing a novel nanoparticle-based immunotherapy platform that harnesses the body's natural tolerance pathway. By mimicking apoptotic cell signals through phosphatidylserine (PS)-containing liposomes, our approach induces regulatory immune responses to "re-educate" the immune system. Our goal is to halt or reverse autoimmune disease progression and prevent unwanted immune reactions, including anti-drug antibodies to biologics and gene therapy vectors.

<https://www.discoveredi.org>



Exhibitor Partner

Novoviah is a biotechnology company focused on enabling precise, ultrasensitive monitoring of antigen-specific T cell responses. Novoviah's Novoleukin Test System is a whole-blood, antigen-stimulated cytokine release assay designed to detect rare antigen-specific T cells with sensitivity beyond conventional methods, while simplifying sample handling for multi-site clinical studies.

Novoviah partners with biopharma and academic teams to deliver tailored immune monitoring solutions across autoimmune disease, vaccine, and immunotherapy programs, with flagship products in Celiac Disease and Type 1 Diabetes. By providing high-resolution insight into antigen-specific immune dynamics, Novoviah's technology supports the development and evaluation of targeted immune-modulating therapies, including approaches focused on immune tolerance.

www.novoviah.com

Get Involved



Malik Mellal
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partner With Us

8th Annual
Antigen-Specific
Immune Tolerance Summit
March 3-5, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Exclusive Platform to Collaborate, Partner & Advance Antigen-Specific Immune Tolerance

As the only event dedicated exclusively to antigen-specific immune tolerance, this summit offers a unique platform to position your therapeutics, technologies, and services in front of a highly curated audience of 60+ pharma and biotech ASIT leaders.

Whether you are advancing into clinical development and looking to elevate your profile, or providing cutting-edge preclinical and translational solutions that enable innovative trial design, this is your opportunity to showcase your expertise, forge strategic partnerships, and accelerate impact within the ASIT community.



Establish your **R&D leadership** and milestones in the ASIT community with high-visibility branding, exhibition opportunities, and **curated networking** events that amplify your expertise and elevate market presence



Demonstrate your ability to deliver efficient **patient screening and recruitment**, including early-disease and niche subset populations, while balancing scientific rigor with real-world clinical viability



Position your **validated biomarker platforms** as critical to antigen confirmation, proof-of-mechanism, and objective clinical endpoints to support smarter trial design and faster decision-making





Highlight **immunophenotyping and validated biomarker strategies** for different autoimmune diseases, suitable for antigen validation, proof-of-mechanism, and objective clinical endpoints




Connect with therapeutic developers seeking computational partners to **identify and prioritize disease-driving antigens** to expand discovery pipelines and enable next-generation tolerizing therapies

Seniority of Attendees



Type of Companies Attending



*Statistics Taken from 8th Antigen Specific Immune Tolerance Summit

Get Involved



Malik Mellal
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

-  as-immunetolerance.com/
-  Tel: +1 617 455 4188
-  Email: info@hansonwade.com



Network with the industry leaders of the immune tolerance field including **COUR**, **Parvus** and **Diamyd**, and big pharma players including **Pfizer**, **Moderna** and **AbbVie**, to discuss translational strategies, collaboration and solutions to the field's biggest challenges



Discover the innovative biotechs emerging in the field such as **Bonsai Biotherapeutics** and **TScan** and their clinical strategies to streamline their novel approaches into their first in-human trials



Learn from the field's leaders by joining the unique, communal, candid discussions about the **successes** and **challenges** in the last 12 months and find **actionable solutions** to your antigen selection, clinical endpoint, dosage and toxicity challenges

Drug Developers*	Register & Pay By Monday, March 2 & Save up to \$200	On the Door Price
Conference + Pre-Conference Workshop Day	\$4,197	\$4,397
Conference Only	\$2,999	\$3,099

Academic & Research Institutes**	Register & Pay By Monday, March 2 & Save up to \$200	On the Door Price
Conference + Pre-Conference Workshop Day	\$3,597	\$3,797
Conference Only	\$2,599	\$2,699

Solution & Service Providers	Register & Pay By Monday, March 2 & Save up to \$200	On the Door Price
Conference + Pre-Conference Workshop Day	\$5,097	\$5,297
Conference Only	\$3,699	\$3,799

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending


Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Hilton Logan Boston Airport
One Hotel Drive
Boston, MA, 02128
United States

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom